Clinical Research Directory
Browse clinical research sites, groups, and studies.
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
Sponsor: Institute of Cancer Research, United Kingdom
Summary
The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes and Mis-Match Repair genes (MLH1, MSH6, MSH2). There are only approximately 150 men with a known BRCA1 or BRCA2 mutation in the UK. Research has shown that these men are at an increased risk of developing prostate cancer but more information is needed about the pathogenesis of prostate cancer in this defined group and the role of screening in these men. The study will offer annual PSA screening to these men to determine the incidence of prostate cancer in this group. The study will also look at new markers of early prostate cancer in this cohort. The power calculations for this study are 850 carriers and 850 controls (age-matched men without BRCA1/2. Mis match repair mutations). It is therefore essential to gain international collaboration to meet the target of recruiting 850 men with these known mutations and a control group of 850 men who have tested negative for a known familial mutation.
Official title: The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer: Targeted Screening in Men at Higher Genetic Risk and Controls
Key Details
Gender
MALE
Age Range
40 Years - 69 Years
Study Type
OBSERVATIONAL
Enrollment
3500
Start Date
2005-03
Completion Date
2030-03
Last Updated
2025-09-26
Healthy Volunteers
No
Conditions
Interventions
PSA test
Patients tested for their level of Prostate Specific Antigen.
Prostate Biopsy
A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
Locations (1)
Cancer Genetics Unit, Royal Marsden Hospital
Sutton, Surrey, United Kingdom